In platinum-resistant ovarian cancer,
Glucocorticoid receptor activation opens a new perspective on chemoresistance
Emerging research elucidates a unique resistance mechanism in ovarian cancer1
Platinum-resistant ovarian cancer (PROC) is an aggressive disease with a poor prognosis and limited treatment options.² Biomarker-targeted treatments are available, but not all women are eligible.3,4
Chapters
The Unmet
Need in PROC
Leading oncologists like Kathleen Moore, MD, MS, FASCO, are looking for more in ovarian cancer management:
- Can treatments be well tolerated and durable?
- Are treatments available for all patients?
Platinum-resistant ovarian cancer by the numbers
~85%
of patients with ovarian
cancer will recur and become resistant to chemotherapy5
3-7 months
of median progression-
free survival with current
treatment options6
~64%
of patients with platinum-
resistant ovarian cancer are not eligible for FDA-approved biomarker therapy3
Video library
Watch as oncologists like Robert L Coleman, MD, FACOG, FACS,
discuss more topics in platinum-resistant ovarian cancer
An evolving scientific paradigm
Emerging research brings hope for clearer understanding
New science is shedding light on mechanisms of resistance. Studies have shown that chemotherapy
activity can be limited by cortisol-driven activation of the glucocorticoid receptor (GR), even at
physiological levels of cortisol.7
References:
1. Veneris JT, Darcy KM, Mhawech-Fauceglia P, et al. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol. 2017;146(1):153-160. doi:10.1016/j.ygyno.2017.04.012 2. Greer A, Gockley A, Manning-Geist B, et al. Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer. Int J Gynecol Cancer. 2021;31(10):1341-1347. doi:10.1136/ijgc-2020-001505 3. Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol. 2023;41(13):2436-2445. doi:10.1200/JCO.22.01900 4. FDA approves mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. FDA. March 22, 2024. Accessed December 11, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant-epithelial-ovarian 5. St Laurent J, Liu JF. Treatment approaches for platinum-resistant ovarian cancer. J Clin Oncol. 2024;42(2):127-133. doi:10.1200/JCO.23.01771 6. Richardson DL, Eskander RN, O’Malley DM. Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review. JAMA Oncol. 2023;9(6):851-859. doi:10.1001/jamaoncol.2023.0197 7. Colombo N, Van Gorp T, Matulonis UA, et al. Relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: a three-arm, randomized, controlled, open-label phase II study. J Clin Oncol. 2023;41(30):4779-4789. doi:10.1200/JCO.22.02624
